Scientists scramble to stop bananas being killed off
Banana plantations in Australia, south-east Asia, Africa and the Middle East have been ravaged by…
read moreThe UK Innovation & Science Seed Fund (formerly known as The Rainbow Seed Fund) is a £27.1m early-stage venture capital fund building and growing technology companies stemming from the UK’s research base.
We help build companies from great science developed in: public laboratories, science and technology campuses and synthetic biology.
We hold investments in some of the UK’s most innovative companies, in areas as diverse as novel antibiotics, research into Alzheimer’s disease, “green” chemicals and airport security.
We’re prepared to invest early and help build a commercial proposition around a technology to attract additional investment needed to get to market.
In order for the Fund to consider investing into your company you must meet at least one of the following criteria:
1. Projects and companies arise from world-class research carried out in our partner laboratories across the UK, including those at Rutherford Appleton Laboratory (STFC), Babraham Institute (BBSRC) and Porton Down (Dstl).
2. Companies are based at our partners’ national science and innovation campuses in Harwell Oxford, Babraham Cambridge, Daresbury Warrington, Norwich, Rothamsted, NOC Southampton, or at one of the Centres for Agricultural innovation.
3. UK Companies working in the field of synthetic biology: Synthetic biology is the design and engineering of biologically-based parts, novel devices and systems and the redesign of existing, natural biological systems.
4. Members of the Fund, who must be working with one of our partner laboratories.
5. Companies working with a Catapult centre under a competitively awarded funded programme or based on intellectual property licensed from a Catapult centre.
A key part of our value in economic terms is in the pivotal early role we play in getting technology companies off the ground, often whilst they are still in the laboratory and before they are ready to spin out. Many of our companies might never have made it, if it had not been for our support and the technologies and services they offer would not have progressed beyond an interesting concept.
In recognition of these achievements, in November 2013 the UKI2S received an additional £10M investment to support the commercialisation of synthetic biology technologies.
This funding was in response to the Synthetic Biology Roadmap, which sets out plans to harness opportunities in the field of synthetic biology. Synthetic biology is one of the eight great technologies highlighted by the UK government as an area of wide-ranging significance and potential economic importance, and in which the UK’s research base is particularly strong.
The UK Innovation & Science Seed Fund is independently managed by Dr. Andrew Muir, Mark White, Oliver Sexton and Pablo Lubroth at Midven.
More information on the Fund can be found at: www.ukinnovationscienceseedfund.co.uk
Banana plantations in Australia, south-east Asia, Africa and the Middle East have been ravaged by…
read moreSoftware leader in the field of genomic data and bioinformatics analysis poised for growth 30…
read moreA Smart Textiles Technology Developed at the National Physical Laboratory London – 17 October 2017 Rainbow…
read more8th May 2017 Nemesis Bioscience today announced the successful completion of its latest funding round,…
read more11 May 2016 Spin out from UK publicly-funded research develops novel laser spectroscopy for environmental,…
read moreCambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…
read more11th January 2016 Contego CEO Adrian Black is looking forward to working in the collaborative…
read moreAntibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17…
read more16 October 2015 Crescendo Biologics Limited, the drug discovery and developer of Humabody™ VH therapeutics,…
read moreLondon-based Synthace provides next-generation software and processes to exponentially improve productivity in bioscience, enabling people…
read moreSummary: Tokamak Energy is working on nuclear fusion, the long-awaited holy grail of the energy…
read moreUpdate your browser to view this website correctly.Update my browser now